Project Details
Description
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
| Status | Active |
|---|---|
| Effective start/end date | 11/1/17 → 11/30/20 |
Funding
- Tocagen Inc.